189 related articles for article (PubMed ID: 11368792)
41. Establishment of a novel host, high-red yeast that stably expresses hamster NADPH-cytochrome P450 oxidoreductase: usefulness for examination of the function of mammalian cytochrome P450.
Ohgiya S; Goda T; Hoshino T; Kamataki T; Ishizaki K
Arch Biochem Biophys; 1997 Jul; 343(2):215-24. PubMed ID: 9224733
[TBL] [Abstract][Full Text] [Related]
42. Adaptive hepatic and intestinal alterations in mice after deletion of NADPH-cytochrome P450 Oxidoreductase (Cpr) in hepatocytes.
Cheng X; Gu J; Klaassen CD
Drug Metab Dispos; 2014 Nov; 42(11):1826-33. PubMed ID: 25147274
[TBL] [Abstract][Full Text] [Related]
43. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
44. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
45. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan.
Uehara S; Uno Y; Hagihira Y; Murayama N; Shimizu M; Inoue T; Sasaki E; Yamazaki H
Xenobiotica; 2015; 45(9):766-72. PubMed ID: 25801057
[TBL] [Abstract][Full Text] [Related]
46. Phanerochaete chrysosporium NADPH-cytochrome P450 reductase kinetic mechanism.
Warrilow AG; Lamb DC; Kelly DE; Kelly SL
Biochem Biophys Res Commun; 2002 Nov; 299(2):189-95. PubMed ID: 12437968
[TBL] [Abstract][Full Text] [Related]
47. Distinct protective mechanisms of HO-1 and HO-2 against hydroperoxide-induced cytotoxicity.
Kim YS; Zhuang H; Koehler RC; Doré S
Free Radic Biol Med; 2005 Jan; 38(1):85-92. PubMed ID: 15589375
[TBL] [Abstract][Full Text] [Related]
48. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450.
Wu L; Gu J; Cui H; Zhang QY; Behr M; Fang C; Weng Y; Kluetzman K; Swiatek PJ; Yang W; Kaminsky L; Ding X
J Pharmacol Exp Ther; 2005 Jan; 312(1):35-43. PubMed ID: 15328377
[TBL] [Abstract][Full Text] [Related]
49. Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates.
Takenaka T; Kazuki K; Harada N; Kuze J; Chiba M; Iwao T; Matsunaga T; Abe S; Oshimura M; Kazuki Y
Drug Metab Pharmacokinet; 2017 Feb; 32(1):61-68. PubMed ID: 28139373
[TBL] [Abstract][Full Text] [Related]
50. Haem and nitric oxide: synergism in the modulation of the endothelial haem oxygenase-1 pathway.
Foresti R; Hoque M; Bains S; Green CJ; Motterlini R
Biochem J; 2003 Jun; 372(Pt 2):381-90. PubMed ID: 12622689
[TBL] [Abstract][Full Text] [Related]
51. Nanocomposites of graphene and cytochrome P450 2D6 isozyme for electrochemical-driven tramadol metabolism.
Cui D; Mi L; Xu X; Lu J; Qian J; Liu S
Langmuir; 2014 Oct; 30(39):11833-40. PubMed ID: 25222611
[TBL] [Abstract][Full Text] [Related]
52. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
[TBL] [Abstract][Full Text] [Related]
53. The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748.
Borowa-Mazgaj B; Mróz A; Augustin E; Paluszkiewicz E; Mazerska Z
Biochem Pharmacol; 2017 Oct; 142():21-38. PubMed ID: 28645477
[TBL] [Abstract][Full Text] [Related]
54. Enzymic conversion of alpha-oxyprotohaem IX into biliverdin IX alpha by haem oxygenase.
Yoshinaga T; Sudo Y; Sano S
Biochem J; 1990 Sep; 270(3):659-64. PubMed ID: 2122884
[TBL] [Abstract][Full Text] [Related]
55. Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase.
Mast N; Liao WL; Pikuleva IA; Turko IV
Arch Biochem Biophys; 2009 Mar; 483(1):81-9. PubMed ID: 19161969
[TBL] [Abstract][Full Text] [Related]
56. Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10.
Kong LM; Qian MR; Hu HH; Xu SY; Yu LS; Jiang HD; Chen SQ; Zeng S
Pharmazie; 2012 May; 67(5):440-7. PubMed ID: 22764579
[TBL] [Abstract][Full Text] [Related]
57. RNA-interference approach to study functions of NADPH : cytochrome P450 oxidoreductase in human hepatocytes.
Feidt DM; Klein K; Nüssler A; Zanger UM
Chem Biodivers; 2009 Nov; 6(11):2084-91. PubMed ID: 19937842
[TBL] [Abstract][Full Text] [Related]
58. Presence of heme oxygenase and NADPH cytochrome P-450 (c) reductase in human corneal epithelium.
Abraham NG; Lin JH; Dunn MW; Schwartzman ML
Invest Ophthalmol Vis Sci; 1987 Sep; 28(9):1464-72. PubMed ID: 3114166
[TBL] [Abstract][Full Text] [Related]
59. [CYP2D6*1, CYP2D6*10 co-expressed with CYPOR in Bac-to-Bac expression system and activity determination].
Qian MR; Chen J; Liu Y; Yu LS; Chen SQ; Zeng S
Yao Xue Xue Bao; 2011 Feb; 46(2):207-12. PubMed ID: 21542294
[TBL] [Abstract][Full Text] [Related]
60. Regulation of NADPH-cytochrome P450 reductase expressed during Douglas-fir germination and seedling development.
Tranbarger TJ; Forward BS; Misra S
Plant Mol Biol; 2000 Sep; 44(2):141-53. PubMed ID: 11117258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
